Corporate Update on Jiangsu Hengrui Pharmaceuticals
Market Snapshot
On Thursday, 22 October 2026, Jiangsu Hengrui Pharmaceuticals (1276.HK) closed the trading session with a modest increase of 0.12 %, pricing at HK $47.44. The stock’s trading volume over the last 24 hours amounted to HK $248.3 million, while the total shares outstanding remain at 7.4 billion. At the close, the company’s market capitalisation stood at HK $367.6 billion.
Key technical indicators for the share are as follows:
- Simple moving average (200 days): HK $60.13
- 52‑week high: HK $80.95 (14 January 2026)
- 52‑week low: HK $43.02 (14 September 2026)
Since the end of the previous month, Hengrui’s share price has appreciated by 4.78 %, reflecting steady investor confidence.
Earnings and Operations
In its latest quarterly report, Jiangsu Hengrui Pharmaceuticals announced a turnaround in its operating profit, moving from a loss to a positive margin. Management attributes this improvement to a strategic realignment of its product mix and increased sales of core eye‑care and anti‑inflammatory formulations.
Gross margins have been modestly pressured by higher input costs in the agricultural‑chemical segment, where prices for key products have declined. Nevertheless, the company’s board emphasized continued investment in contract‑development facilities, which are expected to generate additional revenue streams over the next few years.
Despite these encouraging signs, Hengrui’s earnings guidance remains cautious. The company cited uncertainties surrounding competitive pricing in the eye‑medicine market and the regulatory timeline for new product approvals as key factors influencing future performance.
Peer Performance Context
The following table summarizes the recent performance of related stocks to provide context for Hengrui’s market activity:
| Ticker | Current Price | % Change (24 h) | Market Cap | P/E Ratio |
|---|---|---|---|---|
| 600000.SS – Shanghai Pudong Development Bank | CNY 9.60 | 0 % | CNY 325.1 bn | 6.81 |
| 2328.HK – Picc Property & Casualty | HK $14.98 | 0 % | HK $331 bn | 5.85 |
| 0728.HK – China Telecom – DM | HK $4.37 | -2.94 % | HK $419.6 bn | 11.15 |
| 0267.HK – Citic | HK $11.81 | 0.56 % | HK $360.4 bn | 5.06 |
| 000858.SZ – Wuliangye Yibin | CNY 71.95 | 0 % | CNY 282.8 bn | 21.36 |
The stability of bank and insurance shares contrasts with the modest decline in China Telecom’s shares, highlighting sector‑specific dynamics. Wuliangye Yibin’s recent share‑repurchase program, aimed at reducing capital and enhancing intrinsic value, reflects a broader trend among Chinese listed firms pursuing cancellation‑oriented buybacks.
Company Overview
Jiangsu Hengrui Pharmaceuticals Co. Ltd. is headquartered in Lianyungang, China, and specializes in the research, development, manufacturing, and marketing of a diverse portfolio of pharmaceuticals and packaging materials. Its product range includes anti‑tumor agents, analgesics, anti‑infectives, and various related consumables. The company went public on the Shanghai Stock Exchange on 7 September 2000 and continues to expand its global footprint through strategic product development and manufacturing initiatives.
For further details, the company’s website is available at www.hrs.com.cn .
